DDMAC Says GSK Ad Is Branded Even Without Mention Of Drug Name
This article was originally published in The Pink Sheet Daily
Executive Summary
The journal ad promoted a new treatment for refractory chronic lymphocytic leukemia, but DDMAC said it was obviously Arzerra. This isn't GSK's first time with this problem.
You may also be interested in...
FDA Objects To Claims Based On Low-Quality Evidence In DTC Ads
FDA's Division of Drug Marketing, Advertising and Communications recently used a series of untitled letters to emphasize that the evidence used to make claims in a promotion piece must be of sufficient quality
FDA Objects To Claims Based On Low-Quality Evidence In DTC Ads
FDA's Division of Drug Marketing, Advertising and Communications recently used a series of untitled letters to emphasize that the evidence used to make claims in a promotion piece must be of sufficient quality
GSK/Biovail Zovirax Ads Are Target Of Warning Letter
FDA’s ad division says the website for acyclovir ointment suggests effectiveness in preventing transmission of herpes infection.